Does Epitope Spreading Influence Responsiveness to Rituximab in PLA2R-Associated Membranous Nephropathy?
作者信息
Salant David J
机构信息
Renal Section, Department of Medicine, Boston University Medical Center, Boston, Massachusetts.
出版信息
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1122-1124. doi: 10.2215/CJN.07300619. Epub 2019 Jul 24.
Abstract
摘要
相似文献
1
Does Epitope Spreading Influence Responsiveness to Rituximab in PLA2R-Associated Membranous Nephropathy?表位扩展是否影响磷脂酶A2受体相关膜性肾病对利妥昔单抗的反应性？
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1122-1124. doi: 10.2215/CJN.07300619. Epub 2019 Jul 24.
2
Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.磷脂酶 A2 受体 1 表位在基线时的扩展预示着膜性肾病缓解的可能性降低。
J Am Soc Nephrol. 2018 Feb;29(2):401-408. doi: 10.1681/ASN.2017070734. Epub 2017 Nov 7.
3
Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.抗磷脂酶A2受体自身抗体反应的表位扩展与膜性肾病的不良预后相关。
J Am Soc Nephrol. 2016 May;27(5):1517-33. doi: 10.1681/ASN.2014111061. Epub 2015 Nov 13.
4
Clinical Relevance of Domain-Specific Phospholipase A Receptor 1 Antibody Levels in Patients with Membranous Nephropathy.膜性肾病患者特异性磷脂酶 A 受体 1 抗体水平的临床意义。
J Am Soc Nephrol. 2020 Jan;31(1):197-207. doi: 10.1681/ASN.2019030273. Epub 2019 Dec 16.
5
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.高剂量利妥昔单抗治疗 PLA2R1 相关膜性肾病的早期缓解作用。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24.
6
Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy.在原发性膜性肾病中鉴定出被PLA2R自身抗体识别的主要表位。
J Am Soc Nephrol. 2015 Feb;26(2):302-13. doi: 10.1681/ASN.2014050502. Epub 2014 Oct 6.
7
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.抗磷脂酶A2受体抗体滴度可预测利妥昔单抗治疗后膜性肾病的疗效。
J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.
8
Refining Our Understanding of the PLA2R-Antibody Response in Primary Membranous Nephropathy: Looking Forward, Looking Back.深化我们对原发性膜性肾病中PLA2R抗体反应的理解：回顾与展望。
J Am Soc Nephrol. 2020 Jan;31(1):8-11. doi: 10.1681/ASN.2019111195. Epub 2019 Dec 16.
9
An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.抗磷脂酶 A2 受体定量免疫分析和膜性肾病的表位分析揭示了受体的不同抗原结构域。
PLoS One. 2013 Apr 29;8(4):e61669. doi: 10.1371/journal.pone.0061669. Print 2013.
10
Structural determinants of the dominant conformational epitopes of phospholipase A2 receptor in primary membranous nephropathy.原发性膜性肾病中磷脂酶 A2 受体主要构象表位的结构决定因素。
J Biol Chem. 2022 Mar;298(3):101605. doi: 10.1016/j.jbc.2022.101605. Epub 2022 Jan 19.
引用本文的文献
1
Epitope Spreading in Immune-Mediated Glomerulonephritis: The Expanding Target.免疫介导性肾小球肾炎中的表位扩展：不断扩大的靶标。
Int J Mol Sci. 2024 Oct 16;25(20):11096. doi: 10.3390/ijms252011096.
2
Membranous nephropathy: pathogenesis and treatments.膜性肾病：发病机制与治疗
MedComm (2020). 2024 Jun 29;5(7):e614. doi: 10.1002/mco2.614. eCollection 2024 Jul.
3
Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.原发性膜性肾病患者 PLA2R 抗体的预测价值：一项回顾性研究。
PLoS One. 2024 May 8;19(5):e0302100. doi: 10.1371/journal.pone.0302100. eCollection 2024.
4
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.通过设计降低免疫原性：降低单克隆抗体免疫原性的方法。
BioDrugs. 2024 Mar;38(2):205-226. doi: 10.1007/s40259-023-00641-2. Epub 2024 Jan 23.
5
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.原发性膜性肾病中单克隆抗体治疗的应用进展。
Drugs. 2023 Apr;83(6):507-530. doi: 10.1007/s40265-023-01855-y. Epub 2023 Apr 5.
6
Toxic Occupational Exposures and Membranous Nephropathy.职业性中毒与膜性肾病。
Clin J Am Soc Nephrol. 2022 Nov;17(11):1609-1619. doi: 10.2215/CJN.02930322. Epub 2022 Oct 25.
7
New Insights into the Treatment of Glomerular Diseases: When Mechanisms Become Vivid.肾小球疾病治疗新视角：机制显身手。
Int J Mol Sci. 2022 Mar 24;23(7):3525. doi: 10.3390/ijms23073525.
8
Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.肾脏病学中单剂低剂量利妥昔单抗的临床应答和 B 细胞抑制模式。
Kidney360. 2020 Apr 2;1(5):359-367. doi: 10.34067/KID.0000072020. eCollection 2020 May 28.
9
How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy.时代变了！膜性肾病的抗原宝库。
Front Immunol. 2021 Nov 26;12:800242. doi: 10.3389/fimmu.2021.800242. eCollection 2021.
10
A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.PLA2R 和 THSD7A 在膜性肾病中的作用的新见解。
J Immunol Res. 2021 Jul 14;2021:8163298. doi: 10.1155/2021/8163298. eCollection 2021.
Zotero 插件